Nashville, Tenn.-based Vanderbilt Health has launched an AI partnership to accelerate and improve cancer drug discovery.
Through the partnership, Vanderbilt Health’s Molecular AI Initiative will collaborate with Bertis, an AI-driven proteomics-based precision medicine company, according to a March 3 health system news release.
The joint venture is being led by Tae Hyun Hwang, PhD, professor of surgery, founding director of the Molecular AI Initiative and director of AI Research in the Section of Surgical Sciences at Vanderbilt Health.
Leave a Reply